EU/3/16/1814: Orphan designation for the treatment of malignant mesothelioma
Doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin
Table of contents
Overview
On 12 January 2017, orphan designation (EU/3/16/1814) was granted by the European Commission to TREAT U, S.A., Portugal, for doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin for the treatment of malignant mesothelioma.
Key facts
Active substance |
Doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin
|
Medicine name |
-
|
Intended use |
Treatment of malignant mesothelioma
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/16/1814
|
Date of designation |
12/01/2017
|
Sponsor |
TREAT U, S.A.
Parque Industrial de Taveiro, lote 44 3045-508 Coimbra Portugal Tel. +351 239 800 360 E-mail: info@treatu.pt |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: